Company news

Quest Diagnostics Incorporated (NYSE:DGX) news

Every Quest Diagnostics Incorporated press release and news update in one place — announcements, filings coverage, and company updates for investors.

Quest Diagnostics Incorporated (NYSE:DGX) news

Press releases & updates

Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics

Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics

Apple Health app Users to be Able to Order Labs from Quest Diagnostics

Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference

Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference

Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology

Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026

Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report

Quest Diagnostics Prices $500 Million of Senior Notes

Orkes Raises $60M as Developers Increasingly Use Its Platform to Deploy AI Confidently in Production

Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

Digi Power X Signs First AI Revenue Contract - $19.6 Million, 24-Month SubQ AI Agreement, Validating Operational Launch of AI Factory

City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers

Global Cognitive Assessment and Training Market Surges as North America Dominates | Signant Health, Quest Diagnostics

Digi Power X Enters into Amended and Restated Sales Agreement

Digi Power X Reports Fiscal Year 2025 Financial Results

Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026

Helio Genomics to Make HelioLiver™ Cancer Test Accessible to Quest Diagnostics' Providers

Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors

Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results

Digi Power X Graduates to Cboe Canada

Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer

Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference

Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization

Cleveland Diagnostics Names Jack Kenny as Chairman of the Board

Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 12th Consecutive Year

Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect

Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026

Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium

Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan

Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference

Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the United States

Oracle Names Stephen Rusckowski to the Board of Directors

Quest Diagnostics Declares Quarterly Cash Dividend

Quest Diagnostics to Speak at Citi's 2025 Global Healthcare Conference

New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis

Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

Oxford Partners Expands into Healthcare Real Estate with Appointment of Nelson Udstuen as President of Healthcare Division

Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States

Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration

Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer